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Figure 3
Regenerative indications where child with stored cord blood has
condition
Disease name Family
count
Family count/total
families responding
Autism/apraxia 859 1.99%
Other developmental delay 609 1.41%
Childhood hearing loss 169 0.39%
Cerebral palsy/periventricular
leukomalacia/hypotonia
116 0.27%
Diabetes, type 1 114 0.26%
Inﬂammatory bowel disease 61 0.14%
Hydrocephalus 53 0.12%
Hypoxic-ischemic brain injury 44 0.10%
In-utero brain injury/stroke 38 0.09%
Infant lung disease 30 0.07%
Traumatic brain injury
(post-delivery)
24 0.06%
Muscular dystrophy 15 0.03%
Spinal cord injury 15 0.03%
Diabetes, type II 5 0.01%
Systemic lupus 3 0.01%
TOTAL* 2155 4.98%
*Families may report more than one condition or disease.
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marily under investigation for autologous stem cell infusion
(“regenerative indications”), regardless of whether they
planned to receive a transplant or infusion.
Results: We received 43,259 completed responses. Of the
families completing the questionnaire, 1.87% reported at
least one transplant indication and 17.04% reported at least
one regenerative indication. Figure 1 shows the total number
and percent of families that reported each of the transplant
and regenerative indications listed. For transplant in-
dications, after subtracting families where the child with the
condition was the family member with stored cells, 1.68% of
families reported at least one indication. The most common
indications reported were Hodgkin’s lymphoma (0.33%),
non-Hodgkin’s lymphoma (0.32%), and acute lymphoblastic
leukemia (0.25%) (Figure 2). Similarly, for regenerative in-
dications, after subtracting families where the child with the
conditionwas not the familymemberwith stored cells, 4.98%
of families reported at least one indication. The most com-
mon indications reported were autism/apraxia (1.99%), other
developmental delay (1.41%), and childhood hearing loss
(0.39%) (Figure 3).
Conclusion: Among families who store newborn stem cells
in private cord blood banks, conditions for which stem cell
transplant or infusion may be indicated or under investiga-
tion are relatively prevalent, especially for regenerative
indications.
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Background: Hematopoietic stem cell transplant (HSCT) is
the only curative option for patients with Diamond-Blackfan
anemia (DBA). However, many patients lack suitable related
or unrelated bone marrow donors. Unrelated cord bloodtransplant (UCBT) has successfully been used to treat many
diseases. Advantages of cord blood include: increased like-
lihood of ﬁnding a suitable graft particularly for racial and
ethnic minorities, rapid availability, lack of risk to the donor,
decreased likelihood of transmitting infections, more
permissive HLA mismatching and decreased incidence of
graft versus host disease (GVHD). Here we describe a cohort
of patients who underwent unrelated umbilical cord blood
transplant (UCBT) for DBA at a single center.
Methods: All patients who underwent UCBT for a diagnosis
of DBA from 1996 to 2011 at Duke University Medical Center
were eligible for this retrospective analysis (n¼6). Patients
were diagnosedwith DBA on the basis of pure red cell aplasia
on bone marrow aspirate and when available by ribosomal
mutation testing (n¼3). Descriptive analysis was used for
measures of engraftment, GVHD and survival.
Results: Patients had a median age of 3.1 years (range: 2.5-
20.3 years), 3 were male and all were caucasian. Prior to
UCBT, patients had a median of 34 (range, 6-230) red cell
transfusions and a median ferritin level of 2213ng/ml (range,
319 e 3328 ng/ml). Five of six patients received busulfan
(1mg/kg/dose x 16), cyclophosphamide (50mg/kg/dose x 4)
and equine Anti-thymocyte globulin (30mg/kg/dose x 3). The
most recent patient received ﬂudarabine (30mg/m2 x 5),
melphalan (70mg/m2 x 2), thiotepa (200mg/m2 x 1), alem-
tuzumab (1mg/kg/dose x 3) and hydroxyurea (30mg/kg/day
x 13). Patients were HLA matched at 4/6 (n¼2), 5/6 (n¼2) or
6/6 (n¼2) using low resolution HLA-A and eB and high
resolution eDRB1 typing. Median total nucleated cell dose
pre-cryopreservation was 9.33x107 cells/kg (range: 2.3-
18.4x107 cells/kg). GVHD prophylaxis was cyclosporine and
steroids. All patients engrafted neutrophils (median 22 days,
range: 19-91 days) and platelets (50K, median 81 days,
range: 41-215 days). Two patients experienced grade II-IV
acute GVHD and one had extensive chronic GVHD. With a
median follow up of 5.5 years (range: 2-14 years), 4 of 6 (67%)
patients are alive and well, full donor chimeras, and free of
transfusions. One patient died at day 70 from veno-occlusive
disease and the second died two years post-transplant from
polyserositis, chronic gut GVHD and kidney failure. None of
the 4 surviving patients suffer from any major chronic
medical problems.
Conclusions: UCBT can successfully be used for the treat-
ment of DBA if otherwise suitable donors are not available.
Survival following UCBT is similar to those reported by
CIBMTR following related and unrelated adult donor trans-
plants for DBA.1
1. Roy, V., et. al. BBMT, 2005, 11(8); 600.261
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Hemophagocytic Lymphohistiocytosis (HLH) is a rare im-
munodeﬁciency disease of early childhood characterized by
immune dysregulation due to impaired cytoxic killing and
uncontrolled activation of T cells and macrophages. HLH can
be congenital or acquired; approximately 40 % of children
have an identiﬁed genetic defect. The standard approach to
HLH is several months of therapy with dexamethasone,
cyclosporin and etoposide to achieve disease control, fol-
lowed by allogeneic hematopoietic stem cell transplant
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been surprisingly poor with almost 1/3 of patients suc-
cumbing to early transplant related mortality (TRM). Most of
the fatalities occur due to cardiopulmonary failure. Mortality
is higher than that in other immunodeﬁciency syndromes,
however the reasons for this increased toxicity are unclear.
We hypothesized that prolonged steroid exposure during
HLH therapy may cause the development of cardiac hyper-
trophy. Compromised cardiac reserve could contribute to
poor outcome because of the multiple physiological stressors
associated with transplant.
We reviewed the records of 11 consecutive children under-
going HSCT at our institution from January 2004- December
2012. The age at diagnosis ranged from birth to 60 (median
2.5) months and the age at HSCT from 6-70 (median 9)
months. 8/11 had identiﬁed genetic defects (5 perforin, 2
MUNC, 1 Griscelli). All 11 received pre-HSCT therapy with
etoposide, cyclosporin and dexamethasone. 10/11 were in
complete disease remission at the time of HSCT. Conditioning
was fully ablative in 9/11(Bu, Cy, VP, ATG) and reduced in-
tensity in 2 (Flu/campath). 6 received marrow as stem cell
source. Donors were matched sibling in 1, and unrelated
donor in 5. 5 received unrelated umbilical cord. All patients
except the sibling donor received methylprednisonole at 1-2
mg/kg/day as GVHD prophylaxis. 3 had acute GVHD and
received additional therapy with high dose (>2 mg/kg/day)
steroids.
Pre transplantation echocardiograms were accessible for 6
patients; none had evidence of LVH. Post transplantation
echocardiograms were reviewed for all patients. 7/11 (64%)
never evidenced LVH at any point post-HSCT. TRM in this
group was 3/7 (42%) due to multi-organ system failure
(MOSF) (2) and adenovirus infection (1). 4/11 patients (36%)
developed LVH 1 - 18weeks post-HSCT. TRMwas 100% in this
group, higher than thosewithout LVH (p¼0.58) and all due to
MOSF. Infectious agents were only identiﬁed in 1/4 (adeno /
EBV) and recurrent HLH in one.
In light of these ﬁndings, particular attention to cardiac status
in patients with HLH is highly recommended. Further inves-
tigation is needed to identify pre and post SCT factors
contributing to cardiac hypertrophy. This will allow both pre-
ventativemeasures to be developed and optimalmanagement
to be provided when these patients become critically ill.262
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Chromosome 7 deletions are adverse prognostic factors asso-
ciated with worse outcomes in patients with hematologicalmalignancies. However there are few outcome data for he-
matopoietic stem cell transplant (HSCT) in pediatric patients
with hematological malignancies and chromosome 7 de-
letions. We now describe the outcome in 40 patients with
chromosome 7 abnormalities (ALL, n¼13, AML, n¼11, MDS,
n¼14 and JMML, n¼2) who received an allogeneic HSCTat our
institution between 2001-2013. The median age at the time of
transplant was 9 years (range: 1-18 years). There were 23 pa-
tients with monosomy 7, 12 with 7q- and 5 with 7p-. At the
time of transplant, 16 of the 24 patients with acute leukemia
(ALL/AML) were in CR (9-CR1, 6-CR-2, 1-CR3) and 8/24 had
active disease (3with primary refractory disease, 5 in relapse).
All patients with ALL (13/13),10/11 patientswith AML and 1 /2
patients with JMML received chemotherapy prior to trans-
plant, while patients with MDS received no prior therapy. Pa-
tients received HSCT from MRD (10), MUD (17), MMUD (4) or
haploidentical donors (9). The median time to engraftment
was 19 days (95%CI: 17-20 days). With a median follow up of
857 days (range 5 -4099 days), the 3-year overall survival (OS)
and disease free survival (DFS) for the entire cohort was 60%
and 53%, respectively. The OS and DFS correlated with the
underlying diagnosis with MDS patients having better 3-year
OS andDFS (OS:MDS (77%), AML (36%), ALL (67%), JMML (50%)
and DFS: MDS (64%), AML (36%), ALL (58%), JMML (50%)
Outcome was not signiﬁcantly affected by the type of chro-
mosome 7 deletion (3-year OS: monosomy 7 (59%), 7q- (53%),
7p- (80%), p ¼ 0.528). Upon further subdivision by diagnosis,
patients with MDS that had associated monosomy 7 had
signiﬁcantly better OS compared to patients with AML and
monosomy 7 as well as ALL and monosomy 7 (p ¼ 0.014 and
p ¼ 0.029, respectively). Patients with MDS and associated
chromosome 7 deletions, in particular monosomy 7, may
achieve very good OS and DFS after HSCT. In contrast, patients
with AML do not fare as well after HSCT.263
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Dyskeratosis congenita is a rare inherited bone marrow
failure and cancer predisposition syndrome with multi-
system involvement. While allogeneic hematopoietic stem
cell transplant (HSCT) can cure the bone marrow failure,
reported survival is low, with patients suffering unusual
complications post HSCT. We describe the long term
outcome in 6 patients with mutation proven DC following an
allo-HSCT at our institution between 1997e2011. To our
knowledge this is the ﬁrst report to begin to correlate ge-
notype to phenotype post HSCT. The median age was 4 years
(range: 2e13). 4 patients had mutations in the TINF2 gene, 1
in DKC1 and 1 had a homozygous TERTmutation. 4/6 patients
received reduced intensity conditioning (RIC) regimens and
